SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

27 May 2020 Evaluate

Glenmark Pharmaceuticals has informed that it has enclosed a media release on 27th May 2020 titled ‘Glenmark Pharmaceuticals receives ANDA approval for Chlorzoxazone Tablets USP, 375 mg and 750 mg; Glenmark’s first ANDA approval out of their new US facility’.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2243.00 -4.90 (-0.22%)
20-Apr-2026 09:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.60
Dr. Reddys Lab 1237.30
Cipla 1240.60
Zydus Lifesciences 948.40
Lupin 2329.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×